Baptista-González HA

Language: Spanish
References: 27
Page: 152-156
PDF size: 43.06 Kb.

ABSTRACT

The biobank (Biobase) receives a collection of biological samples established for diagnostic or biomedical research; is organized as a technical unit established criteria in a quality management system, governed under strict work protocols, methodological and systematized guarantying quality and custody of samples and data stored. The Biobase includes a wide range of samples and collection of these designs, ranging from Biobase of samples of healthy individuals and large epidemiological cohort specific to the storage of samples obtained in the process of clinical studies.

REFERENCES

1. Bevilacqua G, Bosman F, Dassesse T, et al. The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch 2010; 456: 449-54.

2. Rudloff U, Bhanot U, Gerald W, et al. Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol 2010; 17: 2229-36.

3. Clement B, Chene G, Degos F. A national collection of liver tumors: lessons learnt from 6 years of biobanking in France. Cancer Lett 2009; 286: 140.

4. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-22.

5. Boulet GA, Horvath CA, Berghmans S, et al. Cervical cytology biobanking: quality of DNA from archival cervical Pap-stained smears. J Clin Pathol 2008; 61: 637-41.

6. Sjoholm MI, Dillner J, Carlson J. Assessing quality and functionality of DNA from fresh and archival dried blood spots and recommendations for quality control guidelines. Clin Chem 2007; 53: 1401-7.

7. Cardoso S, Valverde L, Odriozola A, Elcoroaristizabal X, de Pancorbo MM. Quality standards in Biobanking: authentication by genetic profiling of blood spots from donor’s original sample. Eur J Hum Genet 2010; 18: 848-51.

8. Barnes RO, Parisien M, Murphy LC, Watson PH. Influence of evolution in tumor biobanking on the interpretation of translational research. Cancer Epidemiol Biomarkers Prev 2008; 17: 3344-50.

9. Watson PH, Wilson-McManus JE, Barnes RO, et al. Evolutionary concepts in biobanking-the BC BioLibrary. J Transl Med 2009; 7: 95.

10. McCarty CA, Wilke RA. Biobanking and pharmacogenomics. Pharmacogenomics 2010; 11: 637-41.

11. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010; 11: 177-88.

12. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009; 4: e7960.

13. Zika E, Paci D, Braun A, et al. A European Survey on Biobanks: Trends and Issues. Public Health Genomics 2010.

14. Kaye J. Building a foundation for biobanking: the 2009 OECD guidelines on human biobanks and genetic research databases (HBGRDs). Eur J Health Law 2010; 17: 187-90.

15. Tasse AM, Budin-Ljosne I, Knoppers BM, Harris JR. Retrospective access to data: the ENGAGE consent experience. Eur J Hum Genet 2010; 18: 741-5.

16. Toccaceli V, Fagnani C, Nistico L, et al. Research understanding, attitude and awareness towards biobanking: a survey among Italian twin participants to a genetic epidemiological study. BMC Med Ethics 2009; 10: 4.

17. Goebel JW, Pickardt T, Bedau M, et al. Legal and ethical consequences of international biobanking from a national perspective: the German BMB-EUCoop project. Eur J Hum Genet 2010; 18: 522-5.

18. Deplanque D, Birraux G, Bertoye PH, Postaire E. Collections of human biological samples for scientific purposes. Why do current regulation need to be clarified and how? Therapie 2009; 64: 259-67.

19. Petrini C. “Broad” consent, exceptions to consent and the question of using biological samples for research purposes different from the initial collection purpose. Soc Sci Med 2010; 70: 217-20.

20. Schulte in den Baumen T, Paci D, Ibarreta D. Data protection in biobanks-a European challenge for the long-term sustainability of biobanking. Law Hum Genome Rev 2009: 13-25.

21. Edgerton ME, Grizzle WE, Washington MK. The deployment of a tissue request tracking system for the CHTN: a case study in managing change in informatics for biobanking operations. BMC Med Inform Decis Mak 2010; 10: 32.

22. Chaigneau C, Cabioch T, Beaumont K, Betsou F. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. Clin Chem Lab Med 2007; 45: 1390-5.

23. O’Doherty KC, Hawkins A. Structuring public engagement for effective input in policy development on human tissue biobanking. Public Health Genomics 2010; 13: 197-206.

24. Ries NM, LeGrandeur J, Caulfield T. Handling ethical, legal and social issues in birth cohort studies involving genetic research: responses from studies in six countries. BMC Med Ethics 2010; 11: 4.

25. Avard D, Silverstein T, Sillon G, Joly Y. Researchers’ perceptions of the ethical implications of pharmacogenomics research with children. Public Health Genomics 2009; 12: 191-201.

26. Yuille M, Dixon K, Platt A, et al. The UK DNA banking network: a “fair access” biobank. Cell Tissue Bank 2010; 11: 241-51.

27. Joseph JW, Neidich AB, Ober C, Ross LF. Empirical data about women’s attitudes toward a biobank focused on pregnancy outcomes. Am J Med Genet A 2008; 146: 305-11.